152 related articles for article (PubMed ID: 16980199)
1. Insulin resistance in hypertension and cardiovascular disease.
Lamounier-Zepter V; Ehrhart-Bornstein M; Bornstein SR
Best Pract Res Clin Endocrinol Metab; 2006 Sep; 20(3):355-67. PubMed ID: 16980199
[TBL] [Abstract][Full Text] [Related]
2. [Non-hemodynamic mechanisms of cardiovascular risk in the hypertensive patient: insulin resistance].
Rendina V; Iaccarino G; Iovino G; Morisco C; Vecchione C; Trimarco B
Cardiologia; 1994 Dec; 39(12 Suppl 1):295-8. PubMed ID: 7634286
[TBL] [Abstract][Full Text] [Related]
3. Increased cardiovascular events in hypertensive patients with insulin resistance: a 13-year follow-up.
Bigazzi R; Bianchi S; Buoncristiani E; Campese VM
Nutr Metab Cardiovasc Dis; 2008 May; 18(4):314-9. PubMed ID: 17368007
[TBL] [Abstract][Full Text] [Related]
4. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
5. [Physical activity and the metabolic syndrome].
Westheim A; Os I; Hjermann I
Tidsskr Nor Laegeforen; 1993 Feb; 113(6):723-4. PubMed ID: 8465338
[TBL] [Abstract][Full Text] [Related]
6. Hypertension: a new perspective in therapy and metabolic effect. Part I.
Medina Ruiz A
Bol Asoc Med P R; 1991 Sep; 83(9):399-401. PubMed ID: 1807274
[TBL] [Abstract][Full Text] [Related]
7. Physical activity and the metabolic cardiovascular syndrome.
Westheim A; Os I
J Cardiovasc Pharmacol; 1992; 20 Suppl 8():S49-53. PubMed ID: 1283770
[TBL] [Abstract][Full Text] [Related]
8. Physical activity, cardiorespiratory fitness and insulin resistance: a short update.
Gill JM
Curr Opin Lipidol; 2007 Feb; 18(1):47-52. PubMed ID: 17218832
[TBL] [Abstract][Full Text] [Related]
9. [Hyperinsulinemia and arterial hypertension].
Kuzmanić D; Jelaković B
Lijec Vjesn; 1996 Mar; 118 Suppl 1():57-61. PubMed ID: 8759412
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome: treatment of hypertensive patients.
Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.
Nathanson D; Nyström T
Mol Cell Endocrinol; 2009 Jan; 297(1-2):112-26. PubMed ID: 19038307
[TBL] [Abstract][Full Text] [Related]
12. The metabolic syndrome in hypertension: European society of hypertension position statement.
Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
[TBL] [Abstract][Full Text] [Related]
13. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
Fonseca VA
Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
[TBL] [Abstract][Full Text] [Related]
14. [Insulin resistance and arterial hypertension].
Hrnciarová M; Hrnciar J; Jakubíková K
Vnitr Lek; 1995 Feb; 41(2):111-6. PubMed ID: 7725634
[TBL] [Abstract][Full Text] [Related]
15. Aging-associated insulin resistance predisposes to hypertension and its reversal by exercise: the role of vascular vasorelaxation to insulin.
Li QX; Xiong ZY; Hu BP; Tian ZJ; Zhang HF; Gou WY; Wang HC; Gao F; Zhang QJ
Basic Res Cardiol; 2009 May; 104(3):269-84. PubMed ID: 18931967
[TBL] [Abstract][Full Text] [Related]
16. [Exercise as the cornerstone of cardiovascular prevention].
Boraita Pérez A
Rev Esp Cardiol; 2008 May; 61(5):514-28. PubMed ID: 18462655
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hypertension and other cardiovascular risk factors in patients with metabolic syndrome.
Suzuki T; Homma S
Med Clin North Am; 2007 Nov; 91(6):1211-23, x. PubMed ID: 17964917
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance and polycystic ovary syndrome.
Galluzzo A; Amato MC; Giordano C
Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):511-8. PubMed ID: 18657405
[TBL] [Abstract][Full Text] [Related]
19. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
20. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
Chapman MJ; Sposito AC
Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
